Market Cap (In USD)
115.94 Million
Revenue (In USD)
-
Net Income (In USD)
-97.21 Million
Avg. Volume
3.53 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.39-42.2
- PE
- -
- EPS
- -
- Beta Value
- -0.583
- ISIN
- US14817C1071
- CUSIP
- 14817C107
- CIK
- 1069530
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Richard Jon Barry
- Employee Count
- -
- Website
- https://www.cassavasciences.com
- Ipo Date
- 2000-07-14
- Details
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
More Stocks
-
600368
-
6093
-
MDNA
-
300722
-
EMMNEmmi AG
EMMN
-
603797
-
RAMANEWSShree Rama Newsprint Limited
RAMANEWS
-
XLO